Loading
This closed study tested talazoparib in advanced cancers with selected DNA-repair or PTEN alterations. Its published somatic-BRCA results come from a small mixed-cancer cohort.
Registry active not recruiting, last updated 2026-06-12. Advanced cancers with BRCA1/2, selected other DNA-repair or PTEN alterations. The registry enrollment is estimated at 150; the 2024 publication reports 79 treated participants and 18 in the somatic BRCA1/2 cohort. These are different populations, not conflicting efficacy denominators. No current enrollment route.
Shares Talazoparib, PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares Talazoparib, PARP, Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/